| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 8th September 2020 | Bros. Advisors Lp Baker | 6,151 | Open or private purchase | $47.39 | $291,479.90 |
| 8th September 2020 | Bros. Advisors Lp Baker | 15,807 | Open or private purchase | $47.04 | $743,482.25 |
| 8th September 2020 | Bros. Advisors Lp Baker | 15,172 | Open or private purchase | $47.47 | $720,199.67 |
| 8th September 2020 | Bros. Advisors Lp Baker | 76,473 | Open or private purchase | $47.39 | $3,623,856.64 |
| 8th September 2020 | Bros. Advisors Lp Baker | 185 | Open or private purchase | $45.88 | $8,486.88 |
| 8th September 2020 | Bros. Advisors Lp Baker | 1,220 | Open or private purchase | $47.47 | $57,912.18 |
| 8th September 2020 | Bros. Advisors Lp Baker | 1,272 | Open or private purchase | $47.04 | $59,828.52 |
| 8th September 2020 | Bros. Advisors Lp Baker | 15 | Open or private purchase | $45.88 | $688.13 |
| 4th September 2020 | Bros. Advisors Lp Baker | 26,238 | Open or private purchase | $47.26 | $1,239,984.27 |
| 4th September 2020 | Bros. Advisors Lp Baker | 712 | Open or private purchase | $47.50 | $33,818.72 |
Kodiak Sciences
Kodiak Sciences, Inc. is a a clinical-stage biopharmaceutical company. The company engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline include KSI-301 for wet AMD; K SI-501 for DME and uveitis.
Ticker: KOD
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1468748
Employees: 39
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $270 M (0%)
Marketable Securities, Current: $147 M (18%)
Assets, Current: $419 M (23%)
Property, Plant and Equipment, Net: $1 M (11%)
Other Assets, Noncurrent: $8 M (49%)
Assets: $429 M (19%)
Accounts Payable, Current: $7 M (168%)
Accrued Liabilities, Current: $11 M (0%)
Liabilities, Current: $19 M (60%)
Other Liabilities, Noncurrent: $276 Th (-6%)
Liabilities: $120 M (789%)
Common Stock, Value, Issued: $5 Th (0%)
Common Stock, Shares, Issued: $45 M (0%)
Additional Paid in Capital, Common Stock: $517 M (2%)
Retained Earnings (Accumulated Deficit): $209 M (31%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $594 Th (5840%)
Stockholders' Equity (Parent): $309 M (0%)
Liabilities and Equity: $429 M (19%)
Research and Development: $21 M (-49%)
General and Administrative Expenses: $6 M (-47%)
Operating Income/Loss: $27 M (-48%)
